Breaking Tech News: NXT-ID (NASDAQ: NXTD) Research Note Update from SoundView; New Funding Keeps Wocket Rolling

BOSTON - September 26, 2014 (Investorideas.com Newswire) SoundView Technology Group issues a new research note following recent industry developments, recent uplisting to NASDAQ and funding for NXT-ID Wocket smart wallet. NXT-ID, Inc., (NASDAQ: NXTD) is a biometric authentication company focused on the growing mobile commerce market.

We have adjusted our IV model to account for meaningful revenues coming in 2015 rather than late 2014. The impact is to take our 2015 IV from $11.70 to $8.18. If NXT-ID can meet or exceed our 40K unit/$6.9M revenue projection for 2015 then the stock will converge on our 2016 IV estimate of $17.42.

Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) and Exosome Sciences Announce Clinical Collaboration with Boston University CTE Center To Advance Diagnostic Candidate to Detect CTE in Former NFL Players

SAN DIEGO, PRINCETON, N.J. and BOSTON - September 26, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD) and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that a clinical collaboration with the Boston University (BU) CTE Center has been established to advance a blood-based diagnostic candidate that could identify Chronic Traumatic Encephalopathy (CTE) in living individuals.

CTE is a progressive neurodegenerative disorder that has been found at autopsy in former National Football League (NFL) players. At present, CTE can only be diagnosed through postmortem autopsy. The BU CTE Center has been a leading CTE research center since the disease was first defined.

Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces Dengue Virus Treatment Agreement

SAN DIEGO - September 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into an agreement with Qualtran, LLC that would expand human clinical studies of Hemopurifier® therapy to include individuals infected with dengue virus, a global health threat, which is not addressed with approved drug or vaccine therapies. Aethlon is also in the process of initiating the first FDA approved study of Hemopurifier® therapy in individuals infected with hepatitis c virus (HCV).

Breaking Tech News: NXT-ID (NASDAQ: NXTD) Marketing Update for Wocket™ Smart Wallet

National CNBC Ad Campaign Resumes, Wocket to Exhibit at 2015 CES (Consumer Electronics Show)

SHELTON, Conn. - September 24, 2014 (Investorideas.com Newswire) NXT-ID, Inc., (NASDAQ: NXTD), a biometric authentication company focused on the growing mobile commerce market, issues the following marketing update for the Wocket™ smart wallet.

The Company will be increasing its tactical and strategic marketing plans to spread consumer awareness as well as introduce wocket and wocket number encryption to financial institutions that issue credit and debit cards. The Company also intends to start a merchant education program about the many convenient and secure features of Wocket.